Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709377 | 0.81 | OPRL1 (0.49) | CHRM1 | |
| SCHEMBL20073889 | 0.81 | OPRL1 (0.49) | CHRM1 | |
| SCHEMBL20074505 | 0.78 | CHRM1 (0.44) | CHRM1SLC6A5CHRM2CHRM5GAA | |
| SCHEMBL23799154 | 0.76 | CHRM1 (0.44) | CHRM1SLC6A5CHRM2CHRM5DRD2 | |
| SCHEMBL29709369 | 0.76 | CHRM1 (0.44) | CHRM1SLC6A5CHRM2CHRM5DRD2 | |
| SCHEMBL20073887 | 0.76 | CHRM1 (0.44) | CHRM1SLC6A5CHRM2CHRM5DRD2 | |
| SCHEMBL20073894 | 0.76 | CHRM1 (0.46) | CHRM1CHRM2CHRM5 | |
| SCHEMBL30179338 | 0.76 | CHRM1 (0.46) | CHRM1CHRM2CHRM5 | |
| SCHEMBL21120461 | 0.75 | CHRM1 (0.44) | CHRM1SLC6A5CHRM2CHRM5 | |
| SCHEMBL23798589 | 0.75 | CHRM1 (0.43) | CHRM1CHRM2CHRM5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259787-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
| US-20180105491-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105491-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885SLC6A5 3231/4885CHRM2 2/4885 |
| US-10259787-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885SLC6A5 4141/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.